

## ***2024 Area of Interest for Antimicrobial Stewardship***

### **Antimicrobial Stewardship Areas of Interest**

Effective January 2024, the Antimicrobial Stewardship Investigator Studies Program (MISP) Committee will accept protocols within our current areas of interest (AOI) up to June 25, 2024. This is a competitive process that will be conducted by the Antimicrobial Stewardship MISP review committee. Decisions will be made based on scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

#### **The following areas are of interest to Investigator Studies Program Committee:**

Of particular note, these should be Stewardship focused and not Infection Control focused; while stewardship is strongly tied to infection control, we are not interested in studies describing potential interventions to decrease healthcare-associated infectious complications such as CLABSI, UTI, etc.

- Integration of Antimicrobial Stewardship Programs across integrated delivery networks (IDNs) or accountable care organizations (ACOs) with particular interest in integration with outpatient care and networks/organizations that include acute care and long-term care facilities.
- Studies that evaluate and assess the impact of ASP interventions aimed at reducing/eliminating demonstrated health care disparities related to access to effective antibiotics in the setting of antimicrobial resistance (AMR) and/or appropriate antimicrobial use with an emphasis on sustainability of the intervention(s). These may include measures for health equity and patient level outcomes; stratification of outcomes by

REGAL [race, ethnicity, gender (including sexual orientation, gender identity), age, language preference] or social determinants of health/health access.

- Studies which integrate a CDC One Health approach to AMS and AMR.

The protocols will be collectively reviewed and selected by the Antimicrobial Stewardship MISP Committee.